Sino Biopharmaceutical (STU:SMZ1) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SMZ1 Sino Biopharmaceutical Ltd STU:SMZ1
85 GF Score
Price €0.56
GF Value €0.51
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical FFO?

FFO (Funds from operations) only applies to REITs.

STU:SMZ1
85GF Score
Sino Biopharmaceutical Ltd STU:SMZ1
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sino Biopharmaceutical (STU:SMZ1) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued. The current stock price of €0.56 is trading 10.2% above its estimated GF Value™ of €0.51. GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.

Key valuation signals for STU:SMZ1:

  • FFO:
  • GF Value™: €0.51 vs. price of €0.56 (10.2% above fair value)
  • GF Score™: 85/100 with 3 warning signs

No single metric tells the full story. See the STU:SMZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
85GF Score

Get the complete analysis for STU:SMZ1

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.56
Price
€0.51
GF Value